Search results
Results from the WOW.Com Content Network
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market ...
Lastly, Amgen is an excellent income stock, having increased its annual dividend per share by 249% in the past decade. Amgen still has a long pipeline and will continue to develop newer products.
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...
Amgen shares trade at just 13.4 times forward earnings, a remarkable discount to the S&P 500's multiple of nearly 24. This valuation gap seems overdone, given Amgen's cash-generating power.
The company's stock is trading 13.9 times its forward 12-month earnings estimates, compared with a forward price-to-earnings ratio of 34.2 for Novo Nordisk and 48.49 for Eli Lilly.
On Tuesday, Amgen Inc. (NASDAQ:AMGN) reported second-quarter sales of $8.39 billion, up 20% year over year and beating the consensus of $8.33 billion. Product sales grew 20%, driven by 26% volume ...
Here's a look under the hood to see if now is a good time to buy, sell, or hold the biotech stock. MariTide underwhelms in phase 2 On Monday, Nov. 26, Amgen announced top-line results from a phase ...
Amgen (AMGN) closed the most recent trading day at $246.63, moving -0.28% from the previous trading session.